Chronic fatigue syndrome in women assessed with combined cardiac magnetic resonance imaging

M. A. G. M. Olimulder1 · M. A. Galjee1 · L. J. Wagenaar1 · J. van Es1 · J. van der Palen2,4 · F. C. Visser3 · R. C. W. Vermeulen3 · C. von Birgelen1,5

Abstract
Objective In chronic fatigue syndrome (CFS), only a few imaging and histopathological studies have previously assessed either cardiac dimensions/function or myocardial tissue, suggesting smaller left ventricular (LV) dimensions, LV wall motion abnormalities and occasionally viral persistence that may lead to cardiomyopathy. The present study with cardiac magnetic resonance (CMR) imaging is the first to use a contrast-enhanced approach to assess cardiac involvement, including tissue characterisation of the LV wall.

Methods CMR measurements of 12 female CFS patients were compared with data of 36 age-matched, healthy female controls. With cine imaging, LV volumes, ejection fraction (EF), mass, and wall motion abnormalities were assessed. T2-weighted images were analysed for increased signal intensity, reflecting oedema (i.e. inflammation). In addition, the presence of contrast enhancement, reflecting fibrosis (i.e. myocardial damage), was analysed.

Results When comparing CFS patients and healthy controls, LVEF (57.9 ± 4.3 % vs. 63.7 ± 3.7 %; p < 0.01), end-diastolic diameter (44 ± 3.7 mm vs. 49 ± 3.7 mm; p < 0.01), as well as body surface area corrected LV end-diastolic volume (77.5 ± 6.2 ml/m² vs. 86.0 ± 9.3 ml/m²; p < 0.01), stroke volume (44.9 ± 4.5 ml/m² vs. 54.9 ± 6.3 ml/m²; p < 0.001), and mass (39.8 ± 6.5 g/m² vs. 49.6 ± 7.1 g/m²; p = 0.02) were significantly lower in patients. Wall motion abnormalities were observed in four patients and contrast enhancement (fibrosis) in three; none of the controls showed wall motion abnormalities or contrast enhancement. None of the patients or controls showed increased signal intensity on the T2-weighted images.

Conclusion In patients with CFS, CMR demonstrated lower LV dimensions and a mildly reduced LV function. The presence of myocardial fibrosis in some CFS patients suggests that CMR assessment of cardiac involvement is warranted as part of the scientific exploration, which may imply serial non-invasive examinations.

Keywords Cardiovascular magnetic resonance · Chronic fatigue syndrome · Contrast enhancement · Left ventricular function · Myocardial damage

Introduction
Chronic fatigue syndrome (CFS) is relatively common with an estimated worldwide prevalence of 0.4–1 % [1]. The diagnosis of CFS relies on the presence of unexplained persistent or relapsing chronic fatigue in combination with a cluster of clinical symptoms [1–3]. Various potential aetiologies have been discussed. Ongoing research suggests that latent (chronic active) myocardial infections with Epstein-Barr virus or human cytomegalovirus may trigger CFS, and myocardial fibrosis has been described in this setting [4–6]. In CFS, cardiac involvement has been reported
with reduced left ventricular (LV) dimensions, decreased left ventricular ejection fraction (LVEF), LV wall motion abnormalities, and cardiomyopathies with virus persistence in the myocardium [7–10].

Cardiac magnetic resonance (CMR) imaging may be useful for the non-invasive assessment of cardiac involvement in patients with CFS. This technique permits the examination of cardiac morphology and function, and even tissue characterisation of the LV wall to identify oedema or myocardial fibrosis – the consequences of myocardial inflammation [11]. Contrast-enhancement CMR imaging allows the identification of myocardial fibrosis. T2-weighted imaging, on the other hand, allows the visualisation of myocardial oedema and may be useful for staging myocarditis [12]. In the only other study with CMR imaging in the setting of CFS, 12 patients and 10 matched controls were assessed with cine and tagging imaging, but without the use of the contrast enhancement technique (i.e. without tissue characterisation) [7].

Therefore, in the present study with CMR imaging in patients with confirmed CFS, we used a combined approach of cine, contrast-enhanced, and T2-weighted imaging to assess LV tissue characteristics in addition to cardiac dimensions and function. Data from 12 patients with CFS were then compared with data from an age- and gender-matched group of 36 healthy controls, who were examined with the same imaging protocol.

Methods

Study population

We studied 48 females with a combined CMR approach. A consecutive series of 12 patients with CFS were recruited from a specialised CFS centre, to be examined with CMR. The diagnosis of CFS was based on the revised case definition by Fukuda et al. [3] after ruling out other potential causal diseases. Measurements in the 12 CFS patients were then compared with 36 age-matched, healthy female volunteers without any comorbidities (control group), who provided informed consent prior to CMR examination. The study complied with the Declaration of Helsinki for investigation in human beings, and was performed after approval and supervision of our institutional ethics committee.

CMR data acquisition

CMR examination was performed on a 1.5-T whole body scanner (Achieva scan, Philips Medical Systems, Best, the Netherlands) using commercially available cardiac CMR software. For signal reception, a five-element cardiac synergy coil was used. Electrocardiogram triggering was done with a vector electrocardiogram setup. Subjects were examined in the supine position. Morphological images in the standard views were acquired by using fast field echo cine images (slice thickness 8.0 mm; repetition time 3.4 ms; echo time 1.7 ms; flip angle 60°; matrix 256 × 256).

Subsequently, a breath-hold, black-blood, T2-weighted double-inversion recovery sequence with a fat-saturation pulse was performed in 8–10 short-axis slices, with the following parameters: repetition time 1800–2400 ms; echo time 80 ms; matrix 256 × 256; field of view 32–40 cm; slice thickness 12 mm; number of excitations 1. Myocardial scar was assessed on contrast-enhanced multislice standard views, obtained approximately 10 minutes after intravenous bolus injection of 0.2 mmol gadolinium per kilogram body weight (Shering AG, Berlin, Germany). A three-dimensional Turbo Field Echo inversion recovery T1-weighted sequence was used with the following parameters: repetition time 4.0 ms; echo time 1.3 ms; flip angle 15°; inversion time individually optimised to null myocardial signal (usually between 180–250 ms); matrix 157; slice thickness 10–12 mm).

CMR data analysis and definitions

CMR data were analysed on a workstation using dedicated software for cardiac analysis (Philips MR workspace, Release 2.5.3.0 2007-12-03; Philips, the Netherlands). Left ventricular end-diastolic (ml) and end-systolic volumes (ml), stroke volume (ml), LVEF (%) cardiac output (l/min), and end-diastolic wall mass (g) were calculated from contiguous short-axis loops by segmentation of endocardial and epicardial borders on each frame. Papillary muscles were regarded as part of the ventricular cavity.

The left ventricular wall regions were divided into 17 segments according to a standardised myocardial segmentation model [13]. Normal wall motion was assigned a score of 0, mild hypokinesia 1, severe hypokinesia 2, akiinesia 3, and dyskinesia as 4. The wall motion score index was calculated by dividing the sum of scores in each segment by the total number of observed segments. T2-weighted images were considered if abnormal increased signal intensity was visually observed within the myocardium.

The contrast-enhanced images were independently evaluated by three experienced observers, who were blinded to patient/control characteristics and to the evaluations of each other. Contrast enhancement was defined as a zone of hyperenhancement on the late contrast-enhanced images (in contrast with the dark-grey signal of the normal myocardium). The studies were considered abnormal when at least two independent observers described the same abnormalities with agreement in both the presence of contrast enhancement and its location (same segment), reproducible
Table 1  Baseline demographics of CFS patients and age-matched control group of normal, female subjects

| Variables     | CFS patients | Control group | p value |
|---------------|--------------|---------------|---------|
| Age (years)   | 36 ± 3       | 29 ± 8        | 0.11    |
| Female patients n (%) | 12 (100 %) | 36 (100 %) | NA      |
| Body height (cm) | 168 ± 6.6   | 171 ± 6.4     | 0.28    |
| Body weight (kg) | 60.3 ± 9.6   | 64.7 ± 8.8    | 0.16    |
| BMI           | 21.3 ± 2.2   | 22.2 ± 2.5    | 0.24    |
| BSA           | 1.7 ± 0.2    | 1.7 ± 0.3     | 0.78    |
| HR (beats/min)| 80 ± 16      | 70 ± 13       | 0.09    |
| SBP (mm Hg)   | 133 ± 1      | 124 ± 17      | 0.18    |
| DBP (mm Hg)   | 77 ± 8       | 75 ± 12       | 0.63    |

Data are expressed as mean ± standard deviation or frequencies and percentages. BMI body mass index, BSA body surface area, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, NA not applicable.

Table 2  CMR findings in CFS patients and comparison with an age-matched control group of normal, female subjects

| Variables     | CFS patients | Control group | Mean difference + 95 % CI | p value |
|---------------|--------------|---------------|---------------------------|---------|
| LVEDD (mm)    | 44 ± 3.7     | 49 ± 3.7      | 5 (2.68–7.66)             | <0.05   |
| EDV (ml)      | 129.8 ± 16.0 | 148.9 ± 19.0  | 19.1 (6.75–31.47)         | <0.05   |
| EDV/BSA (ml/m²) | 77.5 ± 6.2   | 86.0 ± 9.3    | 8.4 (2.58–14.27)          | <0.05   |
| LVESD (mm)    | 29.7 ± 4.1   | 30.5 ± 3.2    | 0.8 (–1.48–3.18)          | 0.47    |
| ESV (ml)      | 54.7 ± 10.1  | 54.0 ± 9.2    | 0.7 (–6.99–5.71)          | 0.84    |
| ESV/BSA (ml/m²) | 32.6 ± 4.0   | 30.9 ± 4.8    | 1.7 (1.6 (–4.92–1.48)    | 0.29    |
| IVS (mm)      | 7.9 ± 0.9    | 8.1 ± 1.1     | 0.3 (–0.44–0.97)          | 0.46    |
| EDWM (g)      | 60.6 ± 10.6  | 86.6 ± 11.7   | 26.0 (18.30–33.70)        | <0.05   |
| EDWM/BSA (g/m²) | 39.8 ± 6.5   | 49.6 ± 7.1    | 9.9 (5.16–14.59)          | <0.05   |
| SV (ml)       | 75.0 ± 8.9   | 96.2 ± 11.7   | 21.2 (13.68–28.73)        | <0.05   |
| SV/BSA (ml/m²) | 44.9 ± 4.5   | 54.9 ± 6.3    | 10.0 (6.07–14.03)         | <0.05   |
| CO (l/min)    | 4.9 ± 1.3    | 6.6 ± 1.2     | 1.7 (0.77–2.56)           | <0.05   |
| LVEF (%)      | 57.9 ± 4.3   | 63.7 ± 3.7    | 5.8 (3.19–8.41)           | <0.05   |
| WMSI          | 0.02 ± 0.04  | 0.00 ± 0.00   | 0.02 (–0.04–0.01)         | 0.054   |
| T2 weighted oedema (presence, n) | 0 | NA | – | – |
| CE (presence, n) | 3 | 0 | – | – |

Data are expressed as mean ± standard deviation or frequencies and percentages. CI confidence interval, LVEDD left ventricular end-diastolic diameter, EDV end-diastolic volume, BSA body surface area, LVESD left ventricular end-systolic diameter, ESV end-systolic volume, IVS interventricular septum, EDWM end-diastolic wall mass, SV stroke volume, SVI stroke volume index, CO cardiac output, LVEF left ventricular ejection fraction, WMSI wall motion score index, CE contrast enhancement, NA not applicable.

in more than one contiguous slice and in more than one projection.

Statistical analysis

Continuous variables had a normal distribution and were expressed as mean ± standard error. Categorical data were expressed as frequencies and percentages. To compare our CMR findings in CFS patients, we used age- and gender-matched controls. Student’s t-test and the Mann-Whitney U test were used to compare continuous variables, and chi-square test and Fisher’s exact test were used to compare categorical variables. A p value < 0.05 was considered statistically significant.

Results

Patient characteristics

Twelve female CFS patients and 36 age- and gender-matched controls were analysed in this study. The patients and controls were relatively young (36 ± 13 vs. 29 ± 8 years). All but one CFS patient had a history of infectious mononucleosis disease with IgG antibodies to Epstein-Barr virus or human cytomegalovirus capsid antigen; all of these eleven patients had antibodies to Epstein-Barr virus nuclear antigen. Demographics and baseline characteristics did not differ between both groups (see also Table 1).
CMR results

The complete CMR examination protocol was followed in all CFS patients and controls; image sequences of a high quality could be obtained in all cases. CMR data of our CFS population are presented in Table 2. In CFS patients, LVEF (57.9 ± 4.3 %; \( p < 0.01 \)), end-diastolic diameter (44 ± 3.7), as well as body surface area corrected end-diastolic LV volume (77.5 ± 6.2 ml/m²; \( p < 0.01 \)), LV stroke volume (44.9 ± 4.5 ml/m²; \( p < 0.001 \)), and LV wall mass (39.8 ± 6.5 g/m²; \( p = 0.02 \)) were significantly lower than age- and gender-matched controls. Mild wall motion abnormalities were observed in four CFS patients in the basal and/or mid inferoseptal wall, leading to a wall motion score index of 0.02 ± 0.04; none of the controls showed wall motion abnormalities. Myocardial damage (i.e. fibrosis), as indicated by the presence of contrast enhancement, was observed in three patients who showed such lesions in the basal inferoseptal, septal, and anteroseptal midwall segments. An example is presented in Fig. 1. No contrast enhancement was seen in healthy controls. Only one patient showed both contrast enhancement and wall motion abnormalities. Regional or global oedema, as indicated by an increased signal intensity on T2-weighted images, was not observed in any of the patients.

Discussion

Data of cardiac magnetic resonance imaging

The present CMR study used a combined CMR approach of cine, contrast enhancement, and T2-weighted imaging to assess cardiac dimensions, function, and myocardial tissue characteristics in patients with confirmed CFS and healthy controls. Our data demonstrate a left ventricular size, mass, and function that were lower than in age- and gender-matched controls. Mild wall motion abnormalities were observed in four CFS patients in the basal and/or mid inferoseptal wall, leading to a wall motion score index of 0.02 ± 0.04; none of the controls showed wall motion abnormalities. Myocardial damage (i.e. fibrosis), as indicated by the presence of contrast enhancement, was observed in three patients who showed such lesions in the basal inferoseptal, septal, and anteroseptal midwall segments. An example is presented in Fig. 1. No contrast enhancement was seen in healthy controls. Only one patient showed both contrast enhancement and wall motion abnormalities. Regional or global oedema, as indicated by an increased signal intensity on T2-weighted images, was not observed in any of the patients.
Advertisement placed here.
Advertisement placed here.
and functional LV parameters with CMR, including strain. Contrast enhancement was exclusively observed in viral infections of the myocardium. In our CFS patients, contrast enhancement may help to distinguish between different viral infections by Epstein-Barr virus [19], or human cytomegalovirus; serum antibodies for at least one of these viruses were identified in 11 of our CFS patients. Notably, inferoseptal wall motion abnormalities were observed in one patient with and three patients without contrast enhancement. In patients with myocarditis, the value and interpretation of contrast enhancement can be difficult because of the heterogeneous scar distribution and the generally lower signal intensities. In addition, due to limited voxel resolution, smaller myocardial scars may not be detected. Another explanation for this discrepancy could be the absence of contrast enhancement in the chronic state. To the best of our knowledge, this study is the first to suggest a septal predilection pattern of contrast enhancement and/or wall motion abnormalities in CFS patients. In CFS patients, myocardial fibrosis may lead to ventricular dysfunction, as in patients with Chagas myocarditis, for instance, in whom a relation between the amount of contrast enhancement and late ventricular dysfunction has been described [20].

Clinical implications and consequences

In the present study, in patients with CFS, diagnosis was based on the diagnostic criteria of Fukuda et al. [3]. Future studies might also assess cardiac morphology and function in patients with myalgic encephalomyelitis and its diagnostic criteria [21]. Few data are available on prevalence and extent of cardiac involvement in CFS patients. With our combined CMR approach, we demonstrated in one examination (although in the normal range) lower size, mass, and function of the left ventricle and structural abnormalities of the myocardium, as previously assessed separately with different techniques. Specific treatment of myocarditis remains a challenge [6, 22]. A small, randomised, placebo-controlled trial on the use of antiviral therapy for patients with an Epstein-Barr virus subset of CFS found a clinical improvement after six months [23]. Recently, it has been suggested that Epstein-Barr virus can provoke ventricular tachycardia by both acute and chronic myocardial inflammation, emphasising the clinical importance of this viral infection [19]. To test the hypothesis that Epstein-Barr and/or human cytomegalovirus may lead to ventricular dysfunction, myocardial involvement, and CFS, further studies are warranted that should include early and repeat examinations with a combined CMR approach plus targeted myocardial tissue biopsies. Such serial studies may answer the question of whether some CFS patients develop a dilated cardiomyopathy with the inherent risk of an inferior clinical course [6].

Limitations and technical considerations

We did not perform serial serological tests or myocardial biopsies. It would have been ideal to correlate CMR findings with targeted endomyocardial biopsies. However, this would have involved an invasive procedure without a direct therapeutic implication. In patients with myocarditis, the value and interpretation of contrast enhancement can be
difficult because of heterogeneous scar distribution and the generally lower signal intensities [4, 24–26]. Although our data are unique, findings in this small population of CFS patients cannot answer the question whether the somewhat lower cardiac function may contribute to the reduced exercise capacity or may be a result of lower physical activity. Further assessment of relationships between exercise capacity and CMR parameters in a larger patient population is of interest and should be addressed by future studies.

Conclusion

In patients with chronic fatigue syndrome, CMR demonstrated relatively lower dimensions and a mildly reduced function of the left ventricle. The presence of myocardial fibrosis in some CFS patients suggests that further assessment of cardiac involvement may be warranted as part of a further scientific exploration of the CFS disease. This may imply serial non-invasive examinations with CMR.

Funding There was no external funding of this project.

Conflict of interest M.A.G.M. Olimulder, M.A. Galjee, L.J. Wage-naar, J. van Es, J. van der Palen, F.C. Visser, R.C.W. Vermeulen and C. von Birgelen state that they have no competing interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Devanur LD, Kerr JR. Chronic fatigue syndrome. J Clin Virol. 2006;37:139–50.
2. Baker R, Shaw EJ. Diagnosis and management of chronic fatigue syndrome or myalgic encephalomyelitis (or encephalopathy): summary of NICE guidance. BMJ. 2007;335:446–8.
3. Fukada K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med. 1994;121:953–9.
4. Bohl S, Wassmuth R, Abdel-Aty H, et al. Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging. 2008;24:597–607.
5. Miwa K, Fujita M. Small heart syndrome in patients with chronic fatigue syndrome. Clin Cardiol. 2008;31:328–33.
6. Olimulder MA, van Es J, Galjee MA. The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy. Neth Heart J. 2009;17:481–6.
7. Hollingsworth KG, Hodgson T, Macgowan GA, et al. Impaired cardiac function in chronic fatigue syndrome measured using magnetic resonance cardiac tagging. J Intern Med. 2012;271:264–70.
8. Bowles NE, Bayston TA, Zhang HY, et al. Persistence of enterovirus RNA in muscle biopsy samples suggests that some cases of chronic fatigue syndrome result from a previous, inflammatory viral myopathy. J Med. 1993;24:145–60.
9. Grist NR. Myalgic encephalomyelitis: postviral fatigue and the heart. BMJ. 1989;299:1219.
10. Ishikawa T, Zhu BL, Li DR, et al. Epstein-Barr virus myocarditis as a cause of sudden death: two autopsy cases. Int J Legal Med. 2005;119:231–5.
11. Friedrich MG. Tissue characterization of acute myocardial infarction and myocarditis by cardiac magnetic resonance. JACC Cardiovasc Imaging. 2008;1:652–62.
12. Abdel-Aty H, Simonetti O, Friedrich MG. T2-weighted cardiovascular magnetic resonance imaging. J Magn Reson Imaging. 2007;26:452–9.
13. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the american heart association. Circulation. 2002;105:539–42.
14. Takenaka K, Suzuki Y, Kawakubo K, et al. Cardiovascular effects of 20 days bed rest in healthy young subjects. Acta Physiol Scand Suppl. 1994;616:59–63.
15. Miwa K, Fujita M. Cardiac function fluctuates during exacerbation and remission in young adults with chronic fatigue syndrome and ‘small heart’. J Cardiol. 2009;54:29–35.
16. de Cobelli F, Pironi M, Esposito A, et al. Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol. 2006;47:1649–54.
17. Mahrholdt H, Wagner A, Delugi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114:1581–90.
18. Lerner AM, Zervos M, Dwarkin HJ, et al. Hypothesis: a unified theory of the cause of chronic fatigue syndrome. Infect Dis Clin Pract. 1997;6:239–43.
19. Mavrogeni S, Spargias K, Bratis C, et al. EBV infection as a Cause of VT: evaluation by CMR. JACC Cardiovasc Imaging. 2011;4:561–2.
20. Rochitte CE, Oliveira PF, Andrade JM, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas’ disease: a marker of disease severity. J Am Coll Cardiol. 2005;46:1553–8.
21. Carruthers BM, van de Sande MI, de Meirler KL, et al. Myalgic encephalomyelitis: International consensus Criteria. J Intern Med. 2009;266:327–38.
22. Cocker MS, Abdel-Aty H, Strohm O, et al. Age and gender effects on the extent of myocardial involvement in acute myocarditis – a cardiovascular magnetic resonance (CMR) study. Heart. 2009;95:1925–30.
23. Lerner AM, Beqaj SH, Deeter RG, et al. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome – a cardiovascular magnetic resonance (CMR) study. Heart. 2009;95:1925–30.
24. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109:1250–8.
25. Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414–21.
26. Yokokawa M, Tada H, Koyama K, et al. The characteristics and distribution of the scar tissue predict ventricular tachycardia in patients with advanced heart failure. Pacing Clin Electrophysiol. 2009;32:314–22.